New Era of Preventing End-Stage Kidney Disease Act
- Sponsor
- Rep. Bilirakis, Gus M. [R-FL-12]
- Committees
- Ways and Means Committee (primary)
- Last action
- Feb 24, 2025
Bottom line
The bill aims to improve understanding, diagnosis, treatment, and public awareness of rare kidney diseases, particularly to prevent progression to end-stage kidney disease, through targeted research, enhanced provider education, and policy studies, with a focus on addressing health disparities.
What it actually does
This bill establishes NIDDK Centers of Excellence for rare kidney disease research, mandates a comprehensive study on early intervention and testing for rare kidney disease, expands primary care training to include kidney disease, and authorizes nephrology fellowships focused on health disparities. It also directs the Secretary of HHS to conduct experiments on treatments to delay or eliminate the need for dialysis and transplant, and to study methods for increasing public awareness of rare kidney disease.
Proponents argue
Supporters argue that this bill will significantly advance the understanding and treatment of rare kidney diseases, leading to earlier diagnosis, improved patient outcomes, and a reduction in the burden of end-stage kidney disease. They emphasize the importance of addressing health disparities in kidney disease care and the value of investing in research and specialized training to combat these complex conditions.
Opponents contend
Direct opposition to the bill's core goals of improving kidney disease research and care is not immediately apparent. However, potential concerns from critics might revolve around the allocation of federal resources, arguing that funds could be more effectively used in other areas of public health, or questioning the administrative overhead associated with establishing new centers and conducting multiple studies.
The bill is concise and clearly structured, making it accessible for an informed reader to understand its provisions within a short timeframe.
Section 2
Centers of Excellence on Rare Kidney Disease Research
This section amends the Public Health Service Act to establish NIDDK Centers of Excellence for Rare Kidney Disease Research. These centers will conduct research into the causes, diagnosis, progression, and treatment of rare kidney diseases, including glomerular diseases. They will also work to increase public awareness, especially in rural and underserved communities, and develop resources for clinical research and training. Notably, research funded by these centers must study genotype-phenotype relations and explicitly exclude the consideration of quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) in value assessments.
Supporters argue
Supporters contend that establishing dedicated Centers of Excellence will accelerate scientific discovery, foster collaboration, and translate research into better clinical practices for rare kidney diseases, which are often overlooked. The focus on public awareness and professional training is seen as crucial for early diagnosis and effective management, particularly in underserved areas.
Critics contend
No specific opposition is typically raised against funding medical research centers. However, some might argue that the explicit prohibition on QALYs/DALYs could limit comprehensive economic evaluations of treatments, potentially leading to less efficient resource allocation in healthcare, though disability advocates strongly support this exclusion.
Tradeoffs
The bill balances the need for specialized research with broader public health goals. The prohibition on QALYs/DALYs reflects a tension between economic efficiency metrics and the ethical considerations of valuing life and health for individuals with disabilities.
Section 3
Study on Early Intervention, Testing, and Treatment
This section directs the Secretary of Health and Human Services to conduct a comprehensive study on testing, preventative care, precision medicine, and treatment for rare kidney disease. The study will review the impact of routine urinalysis, the reliability of kidney biopsy, the utility of genetic testing (including for the APOL1 gene), barriers to testing, social/behavioral/biological factors, treatment patterns under various insurance programs, access to nephrologists, efforts to slow ESKD progression, and patient trust among disproportionately affected populations. A report with recommendations must be submitted to Congress within 18 months.
Section 4
Provider Education Enhancements
This section amends the Public Health Service Act to enhance provider education related to kidney disease. Specifically, it expands primary care training programs to include individuals with kidney disease (including rare kidney disease). It also authorizes new fellowships for postgraduate training in nephrology, with specific goals: increasing providers' knowledge of rare kidney disease prevention, diagnosis, and treatment for disproportionately impacted populations (including the APOL1 gene), improving care quality for racial and ethnic minorities, and increasing the number of nephrologists serving these populations.
Section 5
Delaying Kidney Disease Impact through Medicare Experiments and Public Awareness
This section amends the Social Security Act, specifically the Medicare program's End-Stage Renal Disease (ESRD) provisions. It directs the Secretary to conduct experiments evaluating methods for treating rare kidney disease, with a particular focus on treatments that could delay or eliminate the need for dialysis and transplant. Additionally, the Secretary is mandated to conduct a comprehensive study on methods to increase public awareness of rare kidney disease. A report on these experiments and studies, including legislative recommendations, must be submitted to Congress within 24 months.
Prohibits research funded by the Centers of Excellence from considering quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs) in value and cost-effectiveness assessments for studied populations.
Section 2(d)(2)
Why it matters:This is likely a deliberate legislative choice to ensure that research priorities and value assessments do not inadvertently discriminate against individuals with disabilities, a common concern among disability rights advocates regarding QALYs/DALYs. It's a technical but highly consequential policy decision.
Case for: Supporters argue that excluding QALYs/DALYs prevents discrimination against individuals with disabilities by ensuring that research and treatment evaluations do not devalue their lives or health outcomes based on perceived 'quality' or 'disability.' This promotes equitable access to care and research funding.
Case against: Critics of such prohibitions, typically health economists and some policymakers, argue that QALYs/DALYs are valuable tools for objectively assessing the cost-effectiveness of interventions and allocating limited healthcare resources efficiently across a population. They might contend that excluding these metrics could lead to less efficient spending.
Estimated impact: This provision could significantly influence how future research on rare kidney diseases is designed, evaluated, and how its findings are translated into clinical practice and policy, potentially shifting focus away from purely economic efficiency towards broader patient benefit and equity.